Hypertension
Phase 2RCT | Baxdrostat reduces BP in patients with treatment-resistant hypertension.
11 Nov, 2022 | 13:57h | UTCPhase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study – TCTMD
New Drug Helps Tame Uncontrolled High Blood Pressure – HealthDay
RCT | Chlortalidone and Hydrochlorothiazide resulted in similar reductions of CVD in older patients with hypertension.
7 Nov, 2022 | 12:50h | UTCNews Release (not published yet): No difference in heart outcomes found in use of two diuretics to treat blood pressure – American Heart Association
Commentaries:
In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE – TCTMD
Diuretic Comparison Project – DCP – American College of Cardiology
RCT | Discontinuing RAS inhibitors in patients with advanced CKD did not result in a slower decline in eGFR.
4 Nov, 2022 | 13:55h | UTCRenin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this randomized trial, the discontinuation of renin–angiotensin system inhibitors in patients with advanced chronic kidney disease did not lead to a significant between-group difference in the long-term rate of decline in the eGFR. #KidneyWk https://t.co/81EIwG5FQ0 pic.twitter.com/nHNmzlPbHV
— NEJM (@NEJM) November 3, 2022
M-A | Blood pressure lowering and prevention of dementia.
4 Nov, 2022 | 13:46h | UTCNews Release: Best evidence yet that lowering blood pressure can prevent dementia – George Institute for Global Health
Commentary: Meta-Analysis Shows Decrease in Dementia Risk With HTN Treatment – HealthDay
Cross-Sectional Study | Prevalence of and factors associated with high blood pressure among adolescents in India.
3 Nov, 2022 | 13:57h | UTCInvited Commentary: Prevalence of High Blood Pressure Among Youth in India and Association With Future Cardiovascular Disease – JAMA Network Open
Commentary on Twitter
1 in 3 adolescents in India have high BP, which is is associated with the trifecta of overweight/obesity, high blood sugar, high blood lipids, and can be prevented. #OAResearch https://t.co/i2Cth5ol2T
— JAMA Network Open (@JAMANetworkOpen) October 31, 2022
Cohort Study | ARBs linked to decreased incidence of epilepsy compared with other antihypertensives.
19 Oct, 2022 | 14:18h | UTCAssociation Between Angiotensin Receptor Blocker Therapy and Incidence of Epilepsy in Patients With Hypertension – JAMA Neurology (free for a limited period)
Related:
Loneliness and health – Nature Reviews Disease Primers (if the link is paywalled, try this one)
The prevalence of loneliness across 113 countries: systematic review and meta-analysis – The BMJ
Social Isolation and Loneliness – World Health Organization
Psychological Distress and Loneliness Reported by US Adults in 2018 and April 2020 – JAMA
Perspective | The polypill: from concept and evidence to implementation.
18 Oct, 2022 | 12:55h | UTCThe polypill: from concept and evidence to implementation – The Lancet (free registration required)
Related:
Opinion: A new important study supports wider use of the polypill
Perspective: Are Polypills and Population-based Treatment the Next Big Things?
The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era
Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population
Perspective: The Polypill and the Long Journey to Major Impact
Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care
Post-trial follow-up | Longer-term all-cause and cardiovascular mortality with intensive blood pressure control.
17 Oct, 2022 | 12:41h | UTCLonger-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control: A Secondary Analysis of a Randomized Clinical Trial – JAMA Cardiology (free for a limited period)
Author Interview: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control – JAMA
Commentaries:
Benefits of Intensive Blood Pressure Control May Not Persist After Trial Intervention – HCP Live
Related:
Study: Real-world blood pressure measurements vs. measurements taken in the SPRINT trial
Studies: Intensive versus Standard Blood-Pressure Control
Commentary on Twitter
In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpatient systolic BP increased by an average of 7 mm Hg for participants in the intensive treatment group. https://t.co/INSo2zYzhp #Research
— JAMA Cardiology (@JAMACardio) October 12, 2022
Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study.
17 Oct, 2022 | 12:37h | UTCSee also:
Homepage: The Burden of Proof Studies – Nature Medicine
The Burden of Proof studies: assessing the evidence of risk
Health effects associated with vegetable consumption: a Burden of Proof study
Health effects associated with consumption of unprocessed red meat: a Burden of Proof study
Health effects associated with smoking: a Burden of Proof study
Commentary on Twitter
A systematic review using the Burden of Proof meta-analytic method found a significant harmful effect between high systolic #bloodpressure and #ischemicheartdisease. @IHME_UW https://t.co/hewQ9nsCTh
— Nature Medicine (@NatureMedicine) October 10, 2022
Cohort Study | Visit-to-visit SBP variability linked to increased risk of atrial fibrillation in middle-aged and older populations.
17 Oct, 2022 | 12:30h | UTC
Position Statement | Home blood pressure monitoring.
14 Oct, 2022 | 14:16h | UTCRelated:
RCT | No difference in cardiovascular outcomes with evening vs. morning dosing of usual antihypertensives.
12 Oct, 2022 | 14:01h | UTCRelated Consensus Statement: Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension – Journal of Hypertension
Related study (conflicting results): Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction in Randomized Trial
Perspective | Hydrochlorothiazide vs. chlorthalidone – what is the difference?
11 Oct, 2022 | 13:40h | UTCHydrochlorothiazide Versus Chlorthalidone–What is the Difference? – Circulation (free for a limited period)
Related:
Meta-analysis: Chlorthalidone vs. hydrochlorothiazide
Commentary on Twitter
There are big differences among diuretics even within the same class. So let us rethink the class effect. https://t.co/ruE4IYeFf2. Here I discuss what we know about HCTZ vs CTD. pic.twitter.com/cyljdi04v9
— Rajiv Agarwal MD, MS (@AgarwalRajivMD) October 8, 2022
RCT | Intrapartum extended-release nifedipine to prevent severe intrapartum hypertension in patients with severe preeclampsia.
4 Oct, 2022 | 14:37h | UTCTrial of Intrapartum Extended-Release Nifedipine to Prevent Severe Hypertension Among Pregnant Individuals With Preeclampsia With Severe Features – Hypertension (link to abstract – $ for full-text)
News Release: Severe preeclampsia treated safely with nifedipine during labor and delivery – American Heart Association
ESC Scientific Statement | Sex differences in arterial hypertension.
26 Sep, 2022 | 12:10h | UTC
Commentary on Twitter
Terrific work on this important statement on #sexdifferences in #hypertension @EvaGerdts @AnastasiaSMihai @MaasAngela et al! ??https://t.co/jhTXP0NTqJ pic.twitter.com/VBkbKLyV5K
— Dr. Martha Gulati ♥️?❤️??? (@DrMarthaGulati) September 23, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ license
Long-term follow-up of a RCT | Outcomes after catheter-based renal artery denervation for resistant hypertension.
20 Sep, 2022 | 13:33h | UTCLong-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial – The Lancet (free registration required)
Commentary: SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss – TCTMD
Original Study: A Controlled Trial of Renal Denervation for Resistant Hypertension – New England Journal of Medicine
Nonadherence was revealed through measurements of serum concentrations of antihypertensive drugs in one-third of patients with resistant hypertension previously evaluated as adherent.
11 Sep, 2022 | 22:35h | UTC
Review | The management of hypertensive emergencies—is there a “magical” prescription for all?
8 Sep, 2022 | 14:32h | UTC
Review/Perspective | European hypertension guideline downgrading of beta-blockers is not justified.
31 Aug, 2022 | 11:51h | UTC
Salt substitutes vs. regular salt: a quick look.
30 Aug, 2022 | 12:02h | UTCSalt substitutes vs. regular salt: a quick look – Evidently Cochrane
Original Study: Replacing salt with low‐sodium salt substitutes (LSSS) for cardiovascular health in adults, children and pregnant women – Cochrane Library
Related:
Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis – Heart (link to abstract – $ for full-text)
RCT: Reduced-sodium added-potassium salt substitute reduces blood pressure in hypertensive patients
Potassium Enriched Salt Substitution Could Prevent a Large Number of Cardiovascular Deaths
Commentary on Twitter
A quick look at the evidence from @CochranePH on using low-sodium #salt substitutes instead of regular salt. Can salt substitutes reduce #BloodPressure and prevent heart attacks, and are there any risks? A new @CochraneUK blog: https://t.co/iy7CVA8H34 pic.twitter.com/9MRIsEI71Z
— The Cochrane Library (@CochraneLibrary) August 26, 2022
M-A | Urban-rural differences in hypertension prevalence in low-income and middle-income countries, 1990–2020.
30 Aug, 2022 | 11:55h | UTCNews Release: Study shows urban-rural differences in hypertension prevalence in low-income and middle-income countries – News Medical
Commentary on Twitter
?paper alert! In LMICs, is #hypertension more prevalent in urban or rural areas?
Nearly 300 studies from 66 LMICs (>19 million participants) revealed that the rate of change from 1990-2022 appears greater in rural.
It has been so nice contributing to this tremendous work!? https://t.co/EjbRpf83HJ
— Adna Curto (@adna_otti) August 27, 2022
Study shows an increasing incidence of hypertensive disorders in pregnancy.
30 Aug, 2022 | 11:52h | UTCCommentaries:
Increased incidence of hypertensive disorders of pregnancy in young Americans – News Medical
Hypertensive Disorders in Pregnancy on the Rise – AJMC
Commentary on Twitter
Independent birth cohort effect on rates of hypertensive disorders of pregnancy higher incidence in younger generations and persistent racial and ethnic disparities. Increased awareness even among young pregnant people is needed. #OAResearch https://t.co/wNwIZTYLHZ
— JAMA Network Open (@JAMANetworkOpen) August 24, 2022
[News release – not published yet] #ESCCongres – RCT | Evening dosing of blood pressure medication not better than morning dosing.
29 Aug, 2022 | 12:30h | UTCRelated Consensus Statement: Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension – Journal of Hypertension
Related study (conflicting results): Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction in Randomized Trial
Bedtime dosing of antihypertensive medications: systematic review and consensus statement. – “use of bedtime drug dosing of antihypertensive drugs should not be routinely recommended”.
29 Aug, 2022 | 12:28h | UTC
RCT | Self-measurement of blood pressure with a standard device is not enhanced by the use of a connected smartphone application.
26 Aug, 2022 | 13:29h | UTCEffectiveness of Standard vs Enhanced Self-measurement of Blood Pressure Paired With a Connected Smartphone Application: A Randomized Clinical Trial – JAMA Internal Medicine (link to abstract – $ for full-text)
News Release: For Checking Blood Pressure at Home, Basic Cuffs Are Just as Good – UC San Francisco
Commentary: App-enabled device no better than standard device for self-measuring blood pressure – ACP Internist
Commentary on Twitter
Monitoring #bloodpressure at home may help with #bloodpressurecontrol, but using an enhanced device pairing with a smartphone application appears to be no more effective than using a standard device. https://t.co/h6zREImCNv #Research pic.twitter.com/T1zWDlp2pC
— JAMA Internal Medicine (@JAMAInternalMed) August 15, 2022